HPLC · CoA
What Is BPC-157 and What Does BPC-157 Do in Research?
Explainer · 6 min read · Updated 30 September 2026
BPC-157 is a 15 residue synthetic peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of about 1,419 Da, derived from a larger protein found in human gastric juice. Asked what does BPC-157 do in research, the literature points to three main pathways: blood vessel formation linked to VEGFR2 signalling, fibroblast migration through FAK and paxillin, and interaction with the nitric oxide system. All published work is in cell cultures and animal models; it is not an approved medicine in Australia.
Where Does BPC-157 Come From?
BPC-157 comes from a partial sequence of a protein its original investigators named body protection compound, isolated from human gastric juice. The number refers to the fragment rather than a count of residues. The research peptide is fully synthetic: it is assembled by solid-phase peptide synthesis, purified by preparative HPLC and freeze-dried into a white powder. Its proline-rich core (three consecutive prolines at positions 3 to 5, and another at position 8) is thought to contribute to its resistance to enzymatic breakdown in acidic conditions.
| Property | Value |
|---|---|
| Full name | Body protection compound 157, pentadecapeptide |
| Residues | 15 |
| Sequence | GEPPPGKPADDAGLV |
| Molecular formula | C62H98N16O22 |
| Molecular weight | about 1,419 Da |
| Net charge at neutral pH | negative (two aspartate and one glutamate against one lysine) |
| Origin | fragment of a gastric juice protein |
| Form supplied | lyophilised powder, capsules, blend with TB-500 |
| Purity | 98% or higher by HPLC, identity by mass spectrometry |
What Does BPC-157 Do in Laboratory Studies?
In laboratory studies, BPC-157 is used to examine signalling that controls blood vessel formation, cell movement and vascular tone. Each strand of the literature has its own model and reference point.
Angiogenesis and VEGFR2 Signalling
Research reported by the Journal of Molecular Medicine (2017) examined BPC-157 in cultured vascular endothelial cells and in a rat hind limb ischaemia model. The study tracked vascular endothelial growth factor receptor 2 (VEGFR2) expression and internalisation and the downstream Akt and endothelial nitric oxide synthase pathway, alongside tube formation assays.
FAK and Paxillin in Fibroblast Migration
A study in the Journal of Applied Physiology in 2011 used rat tendon fibroblasts to look at outgrowth, survival and migration. It measured phosphorylation of focal adhesion kinase (FAK) and paxillin, two proteins that link the cytoskeleton to the extracellular matrix, and used spreading and transwell assays to quantify movement.
The Nitric Oxide System
A separate line of rat studies from the late 1990s onward, published in pharmacology journals, looked at how BPC-157 behaves when nitric oxide synthesis is blocked or its precursor is added. These designs pair the peptide with L-NAME and L-arginine to probe interactions with the nitric oxide system.
None of these papers are clinical studies, and their findings in cells and animals cannot be read across to people.
What Is the Half-Life of BPC-157?
The half-life of BPC-157 in circulation is short, under 30 minutes in rats and beagle dogs, according to the pharmacokinetic programme reported in Frontiers in Pharmacology in 2022. The same paper traced the labelled peptide into urine and bile as smaller fragments and free amino acids. Circulation time and vial stability are separate questions: as a dry powder the peptide is stable for long periods when stored at minus 20 °C, while reconstituted solution is held cold, at 2 to 8 °C. Sourced figures for other compounds are compared in peptide half-life explained.
How Stable Is BPC-157 in Solution?
BPC-157 is described in the literature as unusually stable for a short linear peptide, including in gastric juice, which is one reason it is studied in oral as well as parenteral models. In the laboratory the usual precautions still apply. Reconstitute with bacteriostatic water, add the diluent gently down the vial wall, swirl instead of shaking, then hold the solution cold and shielded from light. Avoid repeated freezing and thawing. Graduated U-100 syringes are the normal tool for measuring the diluent, and what size syringe suits peptide work explains the barrel sizes and unit scale.
What Is BPC-157/TB-500?
BPC-157/TB-500 is a single vial containing both BPC-157 and TB-500, the synthetic form of thymosin beta 4, supplied as one lyophilised cake. The two peptides are very different: BPC-157 has 15 residues and TB-500 has 43, and the literature places them in different pathways, with thymosin beta 4 best known as an actin-sequestering protein involved in cell motility. Laboratories use the combined format when a protocol calls for both compounds in a fixed ratio. We supply the BPC-157 and TB-500 blend vial in 5 + 5mg and 10 + 10mg, and the practical steps are in how to reconstitute the BPC-157 + TB-500 blend. The design choice between separate vials and a blend is compared in BPC-157 vs TB-500.
Is BPC-157 Legal in Australia?
BPC-157 has no ARTG registration and no approval as an Australian medicine, so it may only be supplied as a research chemical for in-vitro use and never for use in humans or animals. Its scheduling under the Poisons Standard and the way each state and territory applies that standard should be checked directly, because the rules for possession and supply can differ between jurisdictions and change over time. Researchers in sport should also be aware that it is named on the international anti-doping prohibited list. The wider framework is explained in our overview of research peptide law in Australia. None of this is legal advice.
Which BPC-157 Formats Do We Stock?
We stock BPC-157 in several research formats, each vial label showing the compound, quantity, lot and storage temperature, with a certificate of analysis matched to every lot number.
- BPC-157 research vials in 5mg or 10mg, plus a three-vial 10mg value pack for longer study series.
- The BPC-157 starter kit, which adds bacteriostatic water and consumables for reconstitution.
- BPC-157 capsules, 60 capsules of 500 mcg each, for laboratories working with oral formulation models.
- The BPC-157 and TB-500 blend in 5 + 5mg and 10 + 10mg vials, and a recovery research stack with the two compounds in separate vials.
For a laboratory new to the compound, we recommend the starter kit, since it arrives with everything needed to prepare the vial. Related compounds are grouped in the recovery research peptides category. Every product is sold for in-vitro laboratory research to buyers aged 18 and over.
Questions about what does BPC-157 do
Sources
- Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017.
Written by the Macropus Peptides technical team for in-vitro laboratory research reference. Not medical advice; products are not for human or veterinary use and are sold to buyers aged 18 and over.